We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.50 | 0.28% | 1,640.50 | 1,640.00 | 1,640.50 | 1,656.00 | 1,635.00 | 1,642.00 | 5,363,425 | 16:29:57 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.67 | 67.38B |
From Apr 2019 to Apr 2024
By Dimitrios Kontos
GlaxoSmithKline PLC (GSK.LN) said on Tuesday that its drug Nucala has been given approval by the Food and Drug Administration for the treatment of eosinophilic granulomatosis with polyangiitis, previously known as Churg-Strauss syndrome, in the U.S.
Nucala was first approved in 2015 for severe eosinophilic asthma and the company submitted a supplemental application in June 2017, to expand the use of the medicine.
The company said that the FDA's approval is based on results from a 52-week, phase 3 study which was conducted as a collaboration between GlaxoSmithKline and the National Institute of Allergy and Infectious Diseases.
Write to Dimitrios Kontos at dimitrios.kontos@dowjones.com
(END) Dow Jones Newswires
December 12, 2017 11:54 ET (16:54 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
